Osamu Suga Selected Research

ezlopitant

11/2002

Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Osamu Suga Research Topics

Disease

2	Vomiting 08/2008 - 11/2002
1	Allergic Contact Dermatitis 03/2018
1	Contact Dermatitis (Eczema, Contact) 03/2018
1	Drug-Related Side Effects and Adverse Reactions 01/2016
1	Essential Hypertension 01/2016
1	Dizziness (Lightheadedness) 01/2016
1	Hyperkalemia 01/2016
1	Hypertension (High Blood Pressure) 01/2016

Drug/Important Bio-Agent (IBA)

2	Cisplatin (Platino)FDA LinkGeneric 08/2008 - 11/2002
2	AntiemeticsIBA 08/2008 - 11/2002
1	Ointments (Pastes)IBA 03/2018
1	Methylprednisolone FDA LinkGeneric 03/2018
1	betamethasone sodium phosphate FDA LinkGeneric 03/2018
1	Neomycin FDA LinkGeneric 03/2018
1	Eplerenone (Inspra)FDA LinkGeneric 01/2016
1	Mineralocorticoid Receptor AntagonistsIBA 01/2016
1	Antihypertensive Agents (Antihypertensives)IBA 01/2016
1	PotassiumIBA 01/2016
1	(2S,3S)- 2- phenyl- 3- ((5- trifluoromethoxy- 2- methoxy)benzylamino)piperidineIBA 08/2008
1	Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA 08/2008
1	TachykininsIBA 11/2002
1	ezlopitantIBA 11/2002

Therapy/Procedure

1	Intraperitoneal Injections 11/2002
1	Subcutaneous Injections 11/2002